Merck & Company Inc (MRK)vsMaxCyte Inc (MXCT)
MRK
Merck & Company Inc
$111.38
-0.82%
HEALTHCARE · Cap: $277.36B
MXCT
MaxCyte Inc
$0.84
-3.24%
HEALTHCARE · Cap: $90.34M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 199040% more annual revenue ($65.77B vs $33.03M). MRK leads profitability with a 13.6% profit margin vs -135.1%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
MXCT
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.8%
Fair Value
$97.84
Current Price
$111.38
$13.54 premium
Margin of Safety
+44.7%
Fair Value
$1.32
Current Price
$0.84
$0.48 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Weak financial health signals
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -23.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : MXCT
The strongest argument for MXCT centers on Price/Book, Debt/Equity.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : MXCT
The primary concerns for MXCT are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while MXCT is a turnaround play — different risk/reward profiles.
MXCT carries more volatility with a beta of 1.57 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 30/100). MXCT offers better value entry with a 44.7% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →MaxCyte Inc
HEALTHCARE · MEDICAL DEVICES · USA
MaxCyte Inc. (MXCT) is a pioneering company in the field of cell-engineering, distinguished by its innovative Flow Electroporation® technology, which facilitates the efficient and scalable introduction of nucleic acids and proteins into various cell types. Serving a diverse clientele that includes leading biopharmaceutical companies and prominent research institutions, MaxCyte is strategically positioned in the burgeoning cell and gene therapy market. The company's cutting-edge platforms are integral to the development of novel cell-based therapies and vaccines, allowing it to seize substantial growth opportunities within the healthcare landscape. Committed to advancing transformative medical solutions, MaxCyte is set to meet the increasing global demand for innovative therapeutic approaches.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?